Several analysts have recently updated their ratings and price targets for OpGen (NASDAQ: OPGN):

  • 4/13/2019 – OpGen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $0.75 price target on the stock. According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
  • 4/10/2019 – OpGen was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
  • 3/30/2019 – OpGen was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
  • 3/29/2019 – OpGen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $0.75 price target on the stock. According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
  • 3/21/2019 – OpGen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.25 price target on the stock. According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
  • 3/19/2019 – OpGen was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
  • 3/1/2019 – OpGen is now covered by analysts at Alliance Global Partners. They set a “buy” rating and a $2.30 price target on the stock.
  • 3/1/2019 – OpGen was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.75 price target on the stock. According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
  • 2/21/2019 – OpGen was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

NASDAQ:OPGN traded up $0.01 on Monday, hitting $0.58. 600 shares of the company’s stock were exchanged, compared to its average volume of 668,624. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.32 and a quick ratio of 1.20. OpGen Inc has a 52 week low of $0.53 and a 52 week high of $2.90. The stock has a market capitalization of $5.19 million, a PE ratio of -0.26 and a beta of 1.04.

OpGen (NASDAQ:OPGN) last issued its quarterly earnings results on Tuesday, February 26th. The medical research company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.09). OpGen had a negative return on equity of 232.38% and a negative net margin of 453.73%. On average, analysts anticipate that OpGen Inc will post -0.93 earnings per share for the current fiscal year.

In other news, CEO Evan/ Fa Jones bought 417,000 shares of the company’s stock in a transaction dated Thursday, March 28th. The shares were bought at an average cost of $0.60 per share, with a total value of $250,200.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.10% of the stock is currently owned by corporate insiders.

An institutional investor recently bought a new position in OpGen stock. Bank of New York Mellon Corp purchased a new stake in OpGen Inc (NASDAQ:OPGN) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 20,688 shares of the medical research company’s stock, valued at approximately $27,000. Bank of New York Mellon Corp owned 0.24% of OpGen as of its most recent SEC filing. Institutional investors own 5.47% of the company’s stock.

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Recommended Story: How can you know how many shares are floating?

Receive News & Ratings for OpGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.